

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of ameliorating, progress blocking, or therapeutically treating one or more stress-induced diseases comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising lysine and arginine, wherein said stress-induced diseases include one or more diseases selected from the group consisting of dissociated disorders, abnormal gastric motion, and irritable bowel syndrome, ~~and gastric ulcer~~, wherein the lysine is in a salt form ~~salt~~ with glutamic acid.

2. (Original) The method of Claim 1, wherein the lysine is L-lysine.

3. - 4. (Canceled)

5. (Original) The method of Claim 1, wherein said pharmaceutical composition is selected from the group consisting of a food, a drink, or a feed.

6. (Original) The method of Claim 1, wherein said pharmaceutical composition further comprises one or more additional amino acids.

7. (Original) The method of Claim 6, wherein said one or more additional amino acids are in a free form.

8. (Original) The method of Claim 6, wherein said one or more additional amino acids are in a salt form.

9. (Original) The method of Claim 6, wherein said one or more additional amino acids are individually in a free or salt form.

10. (Previously Presented) The method of Claim 6, wherein at least one of said one or more additional amino acids is selected from the group consisting of glutamic acid, and aspartic acid.

11. - 13. (Canceled)

14. (Original) The method of Claim 1, wherein said subject in need thereof suffers from lysine deficiency.

15. (Currently Amended) The method of Claim 1, wherein said stress-induced ~~diseases include one or more diseases selected from the group consisting of disease is~~ irritable bowel syndrome, and ~~gastric ulcer~~.

16. (Original) The method of Claim 1, wherein said effective amount is 0.001 to 13 g/kg/body weight daily on a free lysine form basis.

17. (Original) The method of Claim 1, wherein said effective amount is such that the total intake of lysine is 0.001 to 13 g/kg/body weight daily on a free lysine form basis.

18. (Original) The method of Claim 1, wherein said pharmaceutical composition contains lysine at 90 to 0.1 % by weight on a free form basis.

19. (Original) The method of Claim 1, wherein said pharmaceutical composition contains a lysine content of 1.1- to 3.0-fold the recommended nutritious requirement of lysine.

20. (Original) The method of Claim 1, wherein said subject in need thereof is an animal selected from the group consisting of human, cattle, pig, chicken, and culture fish.

21. (Original) The method of Claim 20, wherein said subject in need thereof is a human.

22. (Original) The method of Claim 1, wherein said pharmaceutical composition further comprises inorganic matter.

23. (Original) The method of Claim 1, wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.

24. (Withdrawn) A pharmaceutical composition comprising lysine and a pharmaceutically acceptable carrier or excipient.

25. (Withdrawn) The pharmaceutical composition of Claim 24, wherein lysine is at a concentration of 90 to 0.1 % by weight on a free form basis.

26. (Withdrawn) The pharmaceutical composition of Claim 24, wherein said pharmaceutical composition further comprises inorganic matter.

27. - 29. (Canceled)

30. (Previously Presented) The method of Claim 1, wherein said method is a method of ameliorating said one or more stress-induced diseases.

31. (Previously Presented) The method of Claim 1, wherein said method is a method of progress blocking said one or more stress-induced diseases.

32. (Previously Presented) The method of Claim 1, wherein said method is a method of therapeutically treating said one or more stress-induced diseases.

33. – 58. (Canceled)